GHO Capital completed the acquisition of X-Chem from Hellman & Friedman and The Carlyle Group.

GHO Capital, a specialist healthcare investment advisor, completed the acquisition of X-Chem, a biotechnology company, from Hellman & Friedman and The Carlyle Group. Financial terms were not disclosed. “We are delighted to have the opportunity to work with the X-Chem team. With its proven DEX discovery platform, X-Chem is the go-to provider for small molecule drug discovery for all of biopharma and poised for future growth,” GHO Capital.